4-fluoro-N-[4-(1-hydroxy-6-nitro-1H-benzoimidazol-2-yl)-phenyl]-benzamide | 691354-04-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-fluoro-N-[4-(1-hydroxy-6-nitro-1H-benzoimidazol-2-yl)-phenyl]-benzamide
• 英文别名: 4-fluoro-N-[4-(1-hydroxy-6-nitrobenzimidazol-2-yl)phenyl]benzamide
• CAS: 691354-04-8
• 化学式: C₂₀H₁₃FN₄O₄
• 分子量: 392.346
• InChiKey: MTKFOCFUFJCTLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-fluoro-N-[4-(1-hydroxy-6-nitro-1H-benzoimidazol-2-yl)-phenyl]-benzamide 、 氯乙酸 在 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 {2-[4-(4-Fluoro-benzoylamino)-phenyl]-6-nitro-benzoimidazol-1-yloxy}-acetic acid
  参考文献：
  名称：

  [EN] TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS MODULANT LE FACTEUR DE TRANSCRIPTION ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2008130368A3
• 作为产物：
  描述：

  N-[4-(aminomethyl)phenyl]-4-fluorobenzamide 在 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-fluoro-N-[4-(1-hydroxy-6-nitro-1H-benzoimidazol-2-yl)-phenyl]-benzamide
  参考文献：
  名称：

  Novel anti-infection agents: Small-molecule inhibitors of bacterial transcription factors

  摘要：

  Structure-based drug design was utilized to identify potent small-molecule inhibitors of proteins within the AraC family of bacterial transcription factors, which control virulence in medically important microbes. These agents represent a novel approach to fight infectious disease and may be less likely to promote resistance development. These compounds lack intrinsic antibacterial activity in vitro and were able to limit a bacterial infection in a mouse model of urinary tract infection. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.072

文献信息

• Transcription Factor Modulating Compounds and Methods of Use Thereof
  申请人：Alekshun Michael N.

  公开号：US20090131481A1

  公开（公告）日：2009-05-21

  Substituted benzimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of using substituted benzimidazole compounds, in, e.g., reducing virulence and infectivity, inhibiting biofilms and treating bacterial infections are also provided.

  提供了一种有用的取代苯并咪唑化合物，可用作抗感染剂，降低微生物的抗药性、毒力或生长。还提供了使用取代苯并咪唑化合物的方法，例如减少病原体的毒力和感染性、抑制生物膜和治疗细菌感染。
• Transcription factor modulating compounds and methods of use thereof
  申请人：Alekshun Michael N.

  公开号：US20110306611A1

  公开（公告）日：2011-12-15

  Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.

  提供了用作抗感染剂的取代苯并咪唑化合物，可以降低微生物的抗药性、毒力或生长。提供了制备和使用取代苯并咪唑化合物的方法，以及制备其药物制剂，例如用于减少抗生素抗性和抑制生物膜的方法。
• TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF
  申请人：LEVY Stuart B.

  公开号：US20110230523A1

  公开（公告）日：2011-09-22

  Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.

  本发明提供了用作抗感染剂的取代苯并咪唑化合物，可以降低微生物的抗性、毒力或生长。本发明还提供了制备和使用取代苯并咪唑化合物的方法，以及制备其药物制剂，例如，在减少抗生素抗性和抑制生物膜方面的应用。
• US7405235B2
  申请人：——

  公开号：US7405235B2

  公开（公告）日：2008-07-29
• Novel anti-infection agents: Small-molecule inhibitors of bacterial transcription factors
  作者：Todd E. Bowser、Victoria J. Bartlett、Mark C. Grier、Atul K. Verma、Taduesz Warchol、Stuart B. Levy、Michael N. Alekshun

  DOI：10.1016/j.bmcl.2007.07.072

  日期：2007.10

  Structure-based drug design was utilized to identify potent small-molecule inhibitors of proteins within the AraC family of bacterial transcription factors, which control virulence in medically important microbes. These agents represent a novel approach to fight infectious disease and may be less likely to promote resistance development. These compounds lack intrinsic antibacterial activity in vitro and were able to limit a bacterial infection in a mouse model of urinary tract infection. (c) 2007 Elsevier Ltd. All rights reserved.